Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/novel-therapeutic-concepts-in-multiple-myeloma-GjnpulaUZd
References (41)
-
P. Greipp, J. Miguel, B. Durie, J. Crowley, B. Barlogie, J. Bladé, M. Boccadoro, J. Child, H. Avet-Loiseau, R. Kyle, J. Lahuerta, H. Ludwig, G. Morgan, R. Powles, K. Shimizu, C. Shustik, P. Sonneveld, P. Tosi, I. Turesson, J. Westin (2005)
International staging system for multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 15
-
H. Ludwig, Z. Adam, R. Hájek, R. Greil, F. Keil, N. Zojer, J. Thaler, H. Gisslinger, A. Lang (2007)
Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.Blood, 110
-
T. Facon, J. Mary, C. Hulin, L. Benboubker, M. Attal, B. Pégourié, M. Renaud, J. Harousseau, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, Claude Martin, P. Casassus, J. Jaubert, H. Jardel, C. Doyen, B. Kolb, B. Anglaret, B. Grosbois, I. Yakoub-Agha, C. Mathiot, H. Avet-Loiseau (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trialThe Lancet, 370
-
M Cavo, F Patriarca, P Tacchetti, M Galli (2007)
Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) in preparation for autologous stem-cell transplantation in newly diagnosed multiple myelomaBlood, 110
-
M. O’Donnell, S. Mcrae, S. Kahn, J. Julian, C. Kearon, B. Mackinnon, D. Magier, C. Strulovitch, T. Lyons, J. Hirsh, Jeffrey Ginsberg (2006)
Evaluation of a VENOus-Return Assist Device (Venowave™) To Treat Severe Post-Thrombotic Syndrome (VENOPTS): A Randomized Controlled Trial.Blood, 108
-
J. Harousseau, M. Attal, P. Moreau, F. Garban, T. Facon, H. Avet-Loiseau (2006)
The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials.Blood, 108
-
A. Dispenzieri, S. Rajkumar, M. Gertz, M. Lacy, R. Kyle, P. Greipp, T. Witzig, J. Lust, S. Russell, S. Hayman, Shaji Kumar, S. Zeldenrust, R. Fonseca, P. Bergsagel, C. Reeder, A. Stewart, V. Roy, R. Dalton (2007)
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.Mayo Clinic proceedings, 82 3
-
Y. Liu, R. Pop, Cameron Sadegh, C. Brugnara, V. Haase, M. Socolovsky (2006)
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo.Blood, 108 1
-
SV Rajkumar, S Jacobus, N Callander, R Fonseca (2008)
Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival and outcomeASCO Proc, 26
-
P. Wijermans, M. Schaafsma, Y. Norden, R. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman, M. Kooi, R. Griend, H. Lokhorst, P. Sonneveld (2008)
Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 StudyBlood, 112
-
C. Straka, P. Liebisch, B. Hennemann, B. Metzner, H. Salwender, L. Kanz, S. Adler-Reichel, W. Ludwig, H. Wandt, M. Bentz, T. Bruemmendorf, M. Hentrich, L. Truemper, M. Freund, H. Wolf, Sezer Orhan, R. Bargou, G. Doelken, N. Schmitz, H. Bernhard, M. Gramatzki, N. Frickhofen, H. Ostermann, R. Schmidmaier, S. Ibach, A. Hinke, H. Einsele, B. Emmerich (2007)
The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study.Blood, 110
-
RA Kyle, T Leong, S Li, MM Oken (2006)
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantationCancer, 106
-
A. Abdelkefi, S. Ladeb, L. Torjman, T. Othman, A. Lakhal, N. Romdhane, H. Omri, M. Elloumi, H. Belaaj, R. Jeddi, L. Aissaouï, H. Ksouri, A. Hassen, F. Msadek, A. Saâd, M. Hsaïri, K. Boukef, A. Amouri, H. Louzir, K. Dellagi, A. Abdeladhim (2008)
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.Blood, 111 4
-
A. Palumbo, S. Bringhen, A. Liberati, T. Caravita, A. Falcone, V. Callea, M. Montanaro, R. Ria, A. Capaldi, R. Zambello, G. Benevolo, D. Derudas, F. Dore, F. Cavallo, F. Gay, P. Falco, G. Ciccone, P. Musto, M. Cavo, M. Boccadoro (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.Blood, 112 8
-
S. Rajkumar, S. Jacobus, N. Callander, R. Fonseca, D. Vesole, M. Williams, R. Abonour, D. Siegel, M. Katz, P. Greipp (2008)
Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wiJournal of Clinical Oncology, 26
-
A. Palumbo, T. Facon, P. Sonneveld, J. Bladé, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, M. Boccadoro, J. Harousseau (2008)
Thalidomide for treatment of multiple myeloma: 10 years later.Blood, 111 8
-
H. Paripati, A. Stewart, S. Cabou, A. Dueck, V. Zepeda, N. Pirooz, C. Ehlenbeck, C. Reeder, J. Slack, J. Leis, J. Boesiger, A. Torloni, R. Fonseca, P. Bergsagel (2008)
Compromised stem cell mobilization following induction therapy with lenalidomide in myelomaLeukemia, 22
-
Shaji Kumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi, D. Gastineau, M. Litzow, R. Fonseca, V. Roy, S. Rajkumar, M. Gertz (2007)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myelomaLeukemia, 21
-
M. Roussou, E. Kastritis, M. Migkou, E. Psimenou, I. Grapsa, C. Matsouka, Despina Barmparousi, E. Terpos, M. Dimopoulos (2007)
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimensLeukemia & Lymphoma, 49
-
B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda‐Roman, Choon-kee Lee, G. Talamo, R. Thertulien, E. Kiwan, S. Krishna, M. Fox, J. Crowley (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.The New England journal of medicine, 354 10
-
A. Palumbo, J. Miguel, P. Sonneveld, P. Moreau, J. Drach, G. Morgan, H. Einsele (2008)
Lenalidomide: a new therapy for multiple myeloma.Cancer treatment reviews, 34 3
-
M. Attal, J. Harousseau, A. Stoppa, J. Sotto, J. Fuzibet, J. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, C. Payen, R. Bataille (1996)
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 335
-
H. Ludwig, E. Tóthová, R. Hájek, J. Drach, Z. Adam, B. Labar, M. Egyed, I. Spicka, H. Gisslinger, I. Kuhn, A. Hinke (2007)
Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.Blood, 110
-
M. Cavo, P. Tosi, E. Zamagni, C. Cellini, P. Tacchetti, F. Patriarca, F. Raimondo, E. Volpe, S. Ronconi, D. Cangini, F. Narni, A. Carubelli, L. Masini, L. Catalano, M. Fiacchini, A. Vivo, A. Gozzetti, A. Lazzaro, S. Tura, M. Baccarani (2007)
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 17
-
Michael Wang, K. Delasalle, S. Thomas, S. Giralt, R. Alexanian (2006)
Complete Remission Represents the Major Surrogate Marker of Long Survival in Multiple Myeloma.Blood, 108
-
N. Gulbrandsen, A. Waage, P. Gimsing, I. Turesson, G. Juliusson, N. Abildgaard, B. Björkstrand, K. Carlson, I. Dahl, K. Forsberg, L. Knudsen, J. Nielsen, U. Mellqvist, I. Nesthus, M. Strandberg, F. Wisløff, P. Fayers (2008)
A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And ToxicityHaematologica-the Hematology Journal, 93
-
C. Mitsiades, Douglas McMillin, Steffen Klippel, T. Hideshima, D. Chauhan, P. Richardson, N. Munshi, K. Anderson (2007)
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.Hematology/oncology clinics of North America, 21 6
-
M. Cavo, F. Patriarca, P. Tacchetti, M. Galli, G. Perrone, M. Petrucci, A. Brioli, S. Bringhen, L. Pantani, P. Tosi, C. Crippa, E. Zamagni, F. Raimondo, F. Narni, C. Cellini, M. Ceccolini, N. Pescosta, M. Goldaniga, V. Montefusco, V. Callea, V. Stefano, T. Caravita, M. Boccadoro, M. Baccarani (2007)
Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).Blood, 110
-
D. Chauhan, T. Hideshima, K. Anderson (2008)
Targeting proteasomes as therapy in multiple myeloma.Advances in experimental medicine and biology, 615
-
T. Mark, J. Stern, J. Furst, D. Jayabalan, F. Zafar, April Larow, R. Pearse, J. Harpel, T. Shore, M. Schuster, J. Leonard, P. Christos, M. Coleman, R. Niesvizky (2008)
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 7
-
JL Harousseau, C Mathiot, M Attal, G Marit (2008)
Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation in previously untreated multiple myeloma: updated data from IFM 2005/01 trialASCO Proc, 26
-
J. Harousseau, C. Mathiot, M. Attal, G. Marit, D. Caillot, Cyrille Hullin, T. Facon, I. Webb, H. Avet-Loiseau, P. Moreau (2008)
Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trialJournal of Clinical Oncology, 26
-
M. Attal, J. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, L. Benboubker, I. Agha, J. Bourhis, L. Garderet, B. Pégourié, C. Dumontet, M. Renaud, L. Voillat, C. Berthou, G. Marit, M. Monconduit, D. Caillot, B. Grobois, H. Avet-Loiseau, P. Moreau, T. Facon (2006)
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.Blood, 108 10
-
T. Lundán, V. Juvonen, M. Mueller, S. Mustjoki, T. Lakkala, V. Kairisto, A. Hochhaus, S. Knuutila, K. Porkka (2008)
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemiaHaematologica, 93
-
J. Wingard, S. Carter, T. Walsh, J. Kurtzberg, T. Small, I. Gersten, A. Mendizabal, H. Leather, D. Confer, L. Baden, R. Maziarz, E. Stadtmauer, J. Bolaños-Meade, Janice Brown, J. Dipersio, M. Boeckh, K. Marr (2007)
Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.Blood, 110
-
S. Rajkumar, P. Richardson, T. Hideshima, K. Anderson (2005)
Proteasome inhibition as a novel therapeutic target in human cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 3
-
R. Kyle, T. Leong, Shuli Li, M. Oken, N. Kay, B. Ness, P. Greipp (2006)
Complete response in multiple myelomaCancer, 106
-
C. Hulin, T. Facon, P. Rodon, B. Pégourié, L. Benboubker, C. Doyen, M. Dib, G. Guillerm, L. Voillat, C. Mathiot, P. Casassus, O. Decaux, M. Flesch, L. Garderet, P. Moreau (2007)
Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.Blood, 110
-
J. Miguel, R. Schlag, Nuriet Khuageva, M. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. Petrucci, A. Palumbo, O. Samoilova, A. Dmoszyńska, K. Abdulkadyrov, R. Schots, B. Jiang, M. Mateos, K. Anderson, D. Esseltine, Kevin Liu, A. Cakana, H. Velde, P. Richardson (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.The New England journal of medicine, 359 9
-
A Dispenzieri, V Rajkumar, MA Gertz, R Fonseca (2007)
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)Mayo Clin Proc, 82
-
P Wijermans, M Schaafsma, Y van Norden, R Ammerlaan (2008)
Melphalan+prednisone vs melphalan+prednisone+thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVONHaematologica, 93
- Publisher
- Springer Journals
- Copyright
- Copyright © 2009 by Springer-Verlag
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-009-0096-8
- Publisher site
- See Article on Publisher Site
Abstract
Treatment of multiple myeloma (MM) has evolved greatly over the past decade, and owing to immunomodulatory agents (thalidomide and lenalidomide) and proteasome inhibition (bortezomib), patients with MM enjoy prolonged survival and improved quality of life. Use of these novel agents has improved the rate of complete remissions in MM, a parameter that has emerged as an important step towards improved survival. Bortezomib should now be considered as an established component of the induction treatment prior to autologous transplantation in younger patients. The combination of melphalan/prednisone with a novel agent is a new standard of care for elderly patients with MM. The beneficial effect of these treatment approaches is also seen in special MM populations, in particular in those with impaired renal function and high-risk cytogenetic features.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jan 1, 2009